Naturecell Co., Ltd. (007390) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Naturecell Co., Ltd. (007390:KRX), powered by AI.

Current Price
₩20,100
P/E Ratio
1053.2
Market Cap
1.3T
Sector
Common Stock
What is the Naturecell Co., Ltd. stock price forecast?

Naturecell Co., Ltd. is currently trading at ₩20,100. View real-time AI analysis on Alpha Lenz.

What is Naturecell Co., Ltd. insider trading activity?

View the latest insider trading data for Naturecell Co., Ltd. on Alpha Lenz.

What is Naturecell Co., Ltd.'s P/E ratio?

Naturecell Co., Ltd.'s P/E ratio is 1053.2.

Naturecell Co., Ltd.

KRX · 007390
₩20,100
Ask about Naturecell Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Naturecell Co., Ltd. trades at a P/E of 1053.2 (premium valuation) with modest ROE of 1.9%. 3Y revenue CAGR of 16.7% highlights clear growth momentum.

Ask for details

Company Overview

Naturecell Co., Ltd. is a biotechnology company primarily focused on the development, production, and commercialization of cell therapy products. The company operates in the burgeoning biopharmaceutical industry, aiming to leverage stem cell technologies to offer innovative treatment options for a range of medical conditions. It engages in research and development efforts to create therapies that can enhance regenerative processes in the human body, particularly targeting diseases that currently have limited treatment avenues. Naturecell Co., Ltd. is dedicated to advancing therapeutic solutions that can address unmet medical needs, potentially impacting healthcare outcomes significantly. The company’s presence in the market underscores the growing importance of biotechnology and regenerative medicine in modern healthcare. By investing in cutting-edge research and employing advanced biotechnologies, Naturecell Co., Ltd. plays a critical role in the evolution of medical treatments, positioning itself as a key player in the sector. With its focus on innovation and the application of cell therapy, the firm contributes to the broader objective of developing sustainable and effective healthcare solutions worldwide.

CEO변대중
SectorCommon Stock
IndustryCommon Stock
0

Company Statistics

FY 2024

Profile

₩1,295,144,625,600Market Cap
₩32,333,908,150Revenue
64.44MShares Out
0Employees

Margins

52.33%Gross
10.94%EBITDA
1.87%Operating
4.19%Pre-Tax
3.79%Net

Valuation

1053.16P/E
19.98P/B
39.94EV/Sales
357.54EV/EBITDA
-802.89P/FCF

Growth (CAGR)

16.68%Rev 3Yr
6.98%Rev 5Yr
N/AOp Inc 3Yr
-19.26%Op Inc 5Yr
N/ANet Inc 3Yr
6.33%Net Inc 5Yr

Returns

1.75%ROA
1.95%ROE
2.17%ROIC

Financial Health

₩28,370,705,740Cash & Cash Equivalents
₩-20,997,597,660Net Debt
11.41%Debt/Equity
9.47Interest Cov

Frequently Asked Questions

Naturecell Co., Ltd. (ticker: 007390) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $1.3T.

The current price is ₩20,100 with a P/E ratio of 1,053.16x and P/B of 19.98x.

ROE is 1.95% and operating margin is 1.87%. Annual revenue is $32.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Naturecell Co., Ltd. (Common Stock) Stock Forecast & Analysis ₩20,100 | Alpha Lenz